Smoking Behaviors in Survivors of Smoking-Related and Non-Smoking-Related Cancers.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 07 2020
Historique:
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 29 12 2020
Statut: epublish

Résumé

The population of cancer survivors is rapidly growing in the US. Tobacco smoking is associated with many cancers; however, whether cigarette smoking behaviors among cancer survivors vary according to cancer type-that is, smoking-related cancers (SRCs) vs non-smoking-related cancers (NSRCs)-remains unclear. To examine cigarette smoking prevalence and behaviors (ie, continuing or quitting smoking) among cancer survivors and to compare them between survivors of SRCs and NSRCs. This study was a cross-sectional analysis of the 2017 National Health Interview Survey, a household survey of civilian US residents who were aged 18 years or older. The National Health Interview Survey is population based and is representative of the US population. Data analysis was performed from June to October 2019. The primary outcomes were prevalence of current cigarette smoking among cancer survivors and prevalence of continuing smoking and quitting smoking after a cancer diagnosis. Secondary outcomes included factors associated with continued smoking vs quitting smoking after a cancer diagnosis. A total of 26 742 respondents (mean [SD] age, 50.97 [18.61] years; 14 646 women [51.76%]) to the 2017 National Health Interview Survey were included in this study. Of the 3068 individuals (9.42%) in the study population who had cancer, 589 (19.96%) were SRC survivors, 2297 (74.50%) were NSRC survivors, 168 (4.96%) were survivors of both SRC and NSRC, and the remaining 14 (0.58%) had missing information about the type of cancer. Four hundred forty-nine SRC survivors (54.08%) were women, compared with 1412 NSRC survivors (54.30%). Ninety-six SRC survivors (15.69%) and 151 NSRC survivors (7.99%) were younger than 45 years. Overall, 372 cancer survivors (13.16%) were current smokers. Current smoking prevalence was higher among survivors of SRCs (145 survivors [19.78%]) compared with NSRC survivors (251 survivors [10.63%]). Among cancer survivors, 309 current smokers at cancer diagnosis (43.96%) reported having successfully quit smoking and 372 (56.04%) reported continuing smoking. Among the continuing smokers, 176 (56.49%) reported an unsuccessful quit attempt in the last 12 months. After cancer diagnosis, SRC survivors had higher odds of continued smoking compared with NSRC survivors (odds ratio [OR], 2.10; 95% CI, 1.12-3.93; P = .02). Men (OR, 1.93; 95% CI, 1.05-3.57; P = .04), those with angina pectoris (OR, 5.40; 95% CI, 1.33-21.91; P = .02), and those with chronic bronchitis (OR, 2.55; 95% CI, 1.05-6.19; P = .04) had higher odds of continued smoking, whereas Hispanic participants (compared with non-Hispanic white participants: OR, 0.18; 95% CI, 0.05-0.68; P = .01) and married participants (compared with never married participants: OR, 0.33; 95% CI, 0.12-0.96; P = .04) had lower odds of continued smoking. These findings suggest that compared with NSRC survivors, SRC survivors may be at higher risk of being cigarette smokers at cancer diagnosis and of continuing smoking afterward. Although smoking cessation interventions are critically important for all cancer survivors, special efforts should target survivors of SRCs.

Identifiants

pubmed: 32614423
pii: 2767827
doi: 10.1001/jamanetworkopen.2020.9072
pmc: PMC7333020
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e209072

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Références

Health Educ Res. 2003 Apr;18(2):156-70
pubmed: 12729175
J Cancer Surviv. 2012 Sep;6(3):333-44
pubmed: 22706885
Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2287-93
pubmed: 16214906
BMC Public Health. 2012 Sep 14;12:784
pubmed: 22974404
Vital Health Stat 2. 2014 Apr;(165):1-53
pubmed: 24775908
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71
pubmed: 17372253
Lung Cancer. 2004 Jun;44(3):287-93
pubmed: 15140541
JAMA Netw Open. 2019 Sep 4;2(9):e1912251
pubmed: 31560387
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744199
J Cancer Surviv. 2019 Feb;13(1):66-74
pubmed: 30612253
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Jpn J Clin Oncol. 2016 May;46(5):462-7
pubmed: 26977054
SSM Popul Health. 2019 Jan 11;7:100349
pubmed: 30723766
J Cancer Surviv. 2011 Jun;5(2):115-22
pubmed: 20812033
Lancet Oncol. 2014 Nov;15(12):e568-80
pubmed: 25439699
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
pubmed: 24890451
Cancer. 2009 Sep 15;115(18 Suppl):4265-9
pubmed: 19731347
Am J Prev Med. 2015 Mar;48(3):326-33
pubmed: 25498551
Cancer. 2007 Dec 1;110(11):2408-19
pubmed: 17932906
J Health Psychol. 2016 Dec;21(12):2813-2823
pubmed: 26044717
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):53-59
pubmed: 29346338
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1013-1019
pubmed: 31725711
BMJ. 2010 Jan 21;340:b5569
pubmed: 20093278
Scand J Urol. 2014 Jun;48(3):239-44
pubmed: 24328689
Oral Oncol. 2007 Feb;43(2):187-92
pubmed: 16860590
Cancer. 2014 Jul 1;120(13):1914-6
pubmed: 24687615
Cancer. 2006 Jan 1;106(1):17-27
pubmed: 16311986
Eur J Surg Oncol. 2002 Dec;28(8):815-20
pubmed: 12477471
J Clin Oncol. 2016 Apr 20;34(12):1315-22
pubmed: 26811527
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):3-9
pubmed: 24420982
Oncol Nurs Forum. 2009 Jul;36(4):429-36
pubmed: 19581233
Clin Dermatol. 1998 Sep-Oct;16(5):625-31
pubmed: 9787975
CA Cancer J Clin. 2014 Jul-Aug;64(4):272-90
pubmed: 24817674
MMWR Surveill Summ. 2012 Jan 20;61(1):1-23
pubmed: 22258477
J Clin Oncol. 2015 May 20;33(15):1647-52
pubmed: 25897151
J Community Health. 2019 Jun;44(3):552-560
pubmed: 30767102
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1450-61
pubmed: 26282629
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2042-7
pubmed: 21980012
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
Springerplus. 2016 Jul 20;5(1):1136
pubmed: 27504234
J Clin Oncol. 2002 Mar 15;20(6):1608-16
pubmed: 11896111
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1783-92
pubmed: 25100826
JAMA Intern Med. 2014 Dec;174(12):1922-8
pubmed: 25317719
Exp Gerontol. 2007 Mar;42(3):160-5
pubmed: 17084574

Auteurs

Ellen R Gritz (ER)

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.

Rajesh Talluri (R)

Department of Data Science, The University of Mississippi Medical Center, Jackson.

Joël Fokom Domgue (J)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Irene Tami-Maury (I)

Department of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston.

Sanjay Shete (S)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
Division of Cancer Prevention and Population Science, The University of Texas MD Anderson Cancer Center, Houston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH